for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Karuna Therapeutics Inc

KRTX.OQ

Latest Trade

86.03USD

Change

2.33(+2.78%)

Volume

37,862

Today's Range

84.26

 - 

87.69

52 Week Range

11.32

 - 

151.87

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
83.70
Open
84.26
Volume
37,862
3M AVG Volume
4.85
Today's High
87.69
Today's Low
84.26
52 Week High
151.87
52 Week Low
11.32
Shares Out (MIL)
26.13
Market Cap (MIL)
2,289.77
Forward P/E
-38.56
Dividend (Yield %)
--

Next Event

Karuna Therapeutics Inc at Wedbush PacGrow Healthcare Virtual Conference

Latest Developments

More

Karuna Therapeutics Reports Q2 Loss Per Share $0.65

Karuna Therapeutics Announces Topline Data From Phase 1B Trial Evaluating KarXT On Experimentally Induced Pain In Healthy Volunteers

Karuna Therapeutics And Psychogenics Announce Drug Discovery Collaboration

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Karuna Therapeutics Inc

Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to address disabling neuropsychiatric conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium.

Industry

Biotechnology & Drugs

Contact Info

33 Arch St Ste 3110

BOSTON, MA

02110-1424

United States

+1.857.4492244

https://karunatx.com/

Executive Leadership

Steven M. Paul

Chairman of the Board, President, Chief Executive Officer

Troy A. Ignelzi

Chief Financial Officer

Andrew Craig Miller

Chief Operating Officer

Giorgio Attardo

Vice President, CMC and Preclinical Development

Stephen K. Brannan

Chief Medical Officer

Key Stats

1.45 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-3.680

2020(E)

-2.828
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
5.83
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-17.27
Return on Equity (TTM)
-17.09

Latest News

Latest News

BRIEF-Karuna Therapeutics Files For Potential Mixed Shelf Offering Size Not Disclosed

* KARUNA THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING

BRIEF-Karuna Announces Positive Outcome Of End-Of-Phase 2 Meeting With FDA For Karxt For Schizophrenia

* KARUNA THERAPEUTICS ANNOUNCES POSITIVE OUTCOME OF END-OF-PHASE 2 MEETING WITH THE FDA FOR KARXT FOR THE TREATMENT OF ACUTE PSYCHOSIS IN PATIENTS WITH SCHIZOPHRENIA

BRIEF-Karuna Therapeutics To Present Additional Data From Phase 2 Clinical Trial Of Karxt For Treatment Of Psychosis In Patients With Schizophrenia

* KARUNA THERAPEUTICS TO PRESENT ADDITIONAL DATA FROM THE PHASE 2 CLINICAL TRIAL OF KARXT FOR THE TREATMENT OF PSYCHOSIS IN PATIENTS WITH SCHIZOPHRENIA AT THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY 2020 ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Puretech Health Sells 555,500 Shares Of Karuna Therapeutics For About $45 Mln

* PURETECH HEALTH - SOLD 555,500 SHARES OF ITS FOUNDED ENTITY KARUNA THERAPEUTICS FOR ABOUT $45 MILLION Source text for Eikon: Further company coverage:

BRIEF-Karuna Therapeutics Reports Qtrly Loss Per Share $0.33

* KARUNA THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES GENERAL BUSINESS UPDATE

BRIEF-Karuna Therapeutics Reports Q4 And Year End 2019 Financial Results And Provides General Business Update

* KARUNA THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND PROVIDES GENERAL BUSINESS UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up